Contributed Content

Garri Zmudze is recognised for his work advancing longevity science — from early diagnostics and personalised medicine to backing the next generation of biotech and animal health founders.

Garri Zmudze, Sergey Jakimov, and Ilya Suharenko launch a new fund for longevity research: LongeVC.

Garri was an angel investor in pet health company Basepaws. Its acquisition offers promising insights into the future of human longevity.

Garri explains the Longevity Science Foundation's work as a nonprofit supporting a decentralized and transparent future of longevity research.

Garri leads LongeVC to invest in diverse founders that will ensure a representative future of longevity and biotech.

LongeVC invests in Interface Biosciences, securing $3 million for pioneering pharmaceutical development from bacterial natural products, marking a strategic advancement towards critical IND-enabling studies

LongeVC Partakes in UNP's $32 Million Series A Funding, Boosting AI-Driven Macrocycle Innovation for Oncology and Beyond

Garri Zmudze will attend this year’s Asia Summit on Global Health (ASGH 2024) as a speaker and investor. He will participate in the "New Frontiers in Healthy Ageing" panel.

As we’re getting to the end of Q2, we prepared a quick summary of all the new additions to LongeVC’s investment portfolio.

LongeVC shares Q3 & Q4 2024 updates, including new investments in Glyphic Bio and Proton Intelligence, as well as key portfolio developments from Turn Bio and Longenesis.

Garri founded the Longevity Science Foundation to fund the diverse treatments contributing to human longevity.

Animal genetics market revenue is predicted to exceed $6.4bn by 2027. Here are some of the pet genetics startups to watch.

Longevity researchers are looking to psychedelics as an avenue for unlocking new understanding about aging and brain health.

Collaboration in biotech will drive the future of the industry. Nonprofits, VCs, and startups must cooperate for success.

Garri leads LongeVC to invest in diverse founders that will ensure a representative future of longevity and biotech.

Garri shares insights on the current state of biotech venture capital, including overvaluations, recent deals, and the impact of events like the SVB collapse.

Decentralization encourages transparency, inclusion, and new funding streams for clinical research.

AI is markedly transforming clinical trials, from enhancing predictive capabilities and patient adherence insights to optimizing trial design and expediting drug development.

I share my drive and LongeVC's strategic investments in advancing an ageless future, emphasising the need for standardised longevity practises and systemic health economics reform

Scientists are researching dog aging, including supplement trials and genetic analysis, to unlock a greater understanding of human longevity.

In a recent interview for DealStreet Asia, Garri discussed the international longevity and biotech investing landscape and provided insights on LongeVC’s planned Fund II.

Garri Zmudze discussed the cancer treatment sector in Asia, its landscape, and its potential with Andrew Tjaardstra from Finance Asia during his recent visit to Hong Kong.

Decentralization and tokenization will enrich the nonprofit and charitable sectors via accepting donations in crypto.

Biotech researchers working closely with decentralized tech innovators indicates that there is an appetite for progress in the longevity sector.

With many asking what’s next for NFTs, charities and nonprofits are exploring and maximizing their power for charitable giving.

New funding sources will spark a wave of transformation in early-stage longevity research.

Healthcare researchers in collaboration with crypto innovators might prove that a longer and healthier lifespan is an attainable reality.

Physicians and founders are rallying behind longevity medicine, and here is what a longer, healthier human lifespan means for the crypto community.

Garri interviews NFT artist Nikita Replyanski on the future of NFTs, his work with the Longevity Science Foundation, and art as community building.

Digitalization like AI and blockchain will make our healthcare system more streamlined and accessible.

Emerging technologies are revolutionizing medicine - person by person and pill by pill.

Longevity will transform how aging looks in society. It will add life to our years, especially later in life.

AI has the power to level up our health and lifespans like never before. Leaders in the biotech sector have been working hard to ensure the responsible and ethical use of AI.

Generative AI can improve our healthcare system with faster drug discovery and treat devastating diseases.

Women help build a more inclusive longevity space. Their dedication, talent, and ability to make an impact stand out.

Events offer diverse industry actors to align on common goals and seek inspiration from other dedicated individuals. This year’s ARDD event will bring the longevity community together in Copenhagen.

Decentralization encourages transparency, inclusion, and new funding streams for clinical research.

AI is markedly transforming clinical trials, from enhancing predictive capabilities and patient adherence insights to optimizing trial design and expediting drug development.

I share my drive and LongeVC's strategic investments in advancing an ageless future, emphasising the need for standardised longevity practises and systemic health economics reform